Last edition
News about "Central Nervous System (CNS) disorders"
Insilico Medicine and SK Biopharmaceuticals have entered an Artificial Intelligence (AI)-powered drug discovery collaboration worth up to USD 2.5 billion to develop innovative therapies for neuroimmune disorders.
Central Nervous System (CNS) Disorders | 23/06/2026 | By News Bureau | 431
Suven Life Sciences will showcase its differentiated CNS clinical portfolio at BIO International Convention 2026, featuring late-stage drug candidates for Alzheimer’s agitation, Major Depressive Disorder (MDD), narcolepsy, Parkinson’s-related cognitive impairment, and other CNS disorders.
Central Nervous System (CNS) Disorders | 22/06/2026 | By News Bureau | 144
Suven Life Sciences Reports Positive Phase 1 Results for SUVN-I6107
Suven Life Sciences has reported positive topline results from the First-in-Human phase 1 study of SUVN-I6107, a Muscarinic M1 Positive Allosteric Modulator (M1-PAM). The successful trial supports the advancement of SUVN-I6107 into phase 2 clinical development.
Central Nervous System (CNS) Disorders | 16/06/2026 | By News Bureau | 153
Teva Completes Acquisition of Emalex Biosciences
Teva has completed its acquisition of Emalex Biosciences, strengthening its late-stage neuroscience pipeline. The deal supports Teva’s Pivot to Growth strategy.
Central Nervous System (CNS) Disorders | 12/06/2026 | By News Bureau | 155
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy